TumorDiagnostik & Therapie 2017; 38(08): 491-495
DOI: 10.1055/s-0043-117822
Schwerpunkt Tumoren der Speiseröhre und des Magens
© Georg Thieme Verlag KG Stuttgart · New York

Multimodale Therapie des fortgeschrittenen Ösophaguskarzinoms

Peter Ebeling
,
Udo Vanhoefer
Further Information

Publication History

Publication Date:
11 October 2017 (online)

Die Behandlung der Ösophaguskarzinome stellt auch heute noch eine erhebliche therapeutische Herausforderung dar. Mit der multimodalen Therapie können die Therapieergebnisse der lokal fortgeschrittenen Ösophaguskarzinome deutlich verbessert werden.

 
  • Literatur

  • 1 Porschen R, Buck A, Fischbach W. et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0 September 2015, AWMF-Registernummer: 021/023OL). Z Gastroenterol 2015; 53: 1288-1347
  • 2 Sjoquist KM, Burmeister BH, Smithers BM. et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
  • 3 Van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
  • 4 Berger AC, Farma J, Scott WJ. et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337
  • 5 Mariette C, Dahan L, Mornex F. et al. Surgery alone vs. chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422
  • 6 Stahl M, Stuschke M, Lehmann N. et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317 ; Erratum in: J Clin Oncol 2006; 24: 531
  • 7 Cunningham D, Allum WH, Stenning SP. et al. Perioperative Chemotherapy vs. Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med 2006; 355: 11-20
  • 8 Ychou M, Boige V, Pignon JP. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721
  • 9 Stahl M, Walz MK, Stuschke M. et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856
  • 10 Al-Batran SH, Homann N, Schmalenberg H. et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) vs. epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol 2017; 35 (suppl 15): abstr 4004 DOI: 10.1200/JCO.2017.35.15_suppl.4004 .